Stock data
Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc. (MGX) reported revenue of US$25.21M and net income of -US$87.87M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$25.21M | — | -US$96.01M | -US$87.87M | — |
| 2024 | US$52.30M | — | -US$88.90M | -US$78.06M | — |
| 2023 | US$44.76M | — | -US$78.49M | -US$68.25M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$27.48M | — |
| 2026-03-31 | US$1.25M | -US$23.06M | — |
| 2025-12-31 | US$3.91M | -US$22.53M | — |
| 2025-09-30 | US$8.66M | -US$20.39M | — |
| 2025-06-30 | US$8.51M | -US$19.91M | — |
| 2025-03-31 | US$4.13M | -US$25.04M | — |
| 2024-12-31 | US$9.61M | -US$23.40M | — |
| 2024-09-30 | US$11.51M | -US$18.77M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.